Clinical Trial Update: Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with unresectable stage III–IV melanoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Recurrent Melanoma, Stage IIIc Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-05-30